Navigation Links
Covance Reports Second Quarter Revenue of $518 Million, GAAP EPS of $0.61, and Pro Forma EPS of $0.66
Date:7/27/2011

PRINCETON, N.J., July 27, 2011 /PRNewswire/ -- Covance Inc. (NYSE: CVD) today reported GAAP earnings for its second quarter ended June 30, 2011 of $0.61 per diluted share.  Included in second quarter results is $0.05 per diluted share in costs from the previously-announced restructuring actions. Excluding these costs, earnings per diluted share were $0.66 in the quarter.  

"On a consolidated basis, second quarter net revenues grew 9.1% year-on-year and pro forma operating margin (when excluding $4.6 million of restructuring costs), expanded 80 basis points sequentially to 10.3%," said Joe Herring, Chairman and Chief Executive Officer.  "In Early Development, revenues grew 11.4% year-on-year to $231.8 million. Revenues were up sequentially in toxicology, analytical chemistry, clinical pharmacology, and discovery support, driving a $7.8 million increase in revenues and a 240 basis point increase in pro forma operating margin from last quarter to 14.2%.  In Late-Stage Development, revenues grew 7.3% year-on-year and 3.0% sequentially driven by the continued strong performance in clinical development coupled with the weakening of the US dollar, which more than offset the impact of continued project delays and cancellations in central laboratories. Pro forma operating margin in the segment was 20.0%.  

"On the commercial front, adjusted net orders in the second quarter were $614 million, representing an adjusted book-to-bill of 1.18 to 1 led by continued strong orders across all phases of clinical development.  Looking forward, we are encouraged by the increasing demand for our early development services, including toxicology, as well as the continued robust pipeline of clinical development proposals. In order to fully capitalize on the market opportunities we are seeing, several dozen incremental sales and marketing professionals were hi
'/>"/>

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Covance to Present at Bairds 2011 Growth Stock Conference
2. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2011 Financial Results Conference Call
3. Covance to Present at the 2nd Annual Morningstar/NYSSA Healthcare Conference
4. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
5. Covance Reports Fourth Quarter Revenue of $492 Million, GAAP EPS of $0.45, and Pro Forma EPS of $0.56
6. Covance Reports Third Quarter Financial Results and Takes Actions to Strengthen Future Performance
7. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
8. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
9. Covance Board Authorizes $250 Million Stock Buyback
10. Covance to Present at Morgan Stanley Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of the "An Introduction to ... - November 2-3, 2015)" conference to their ... a comprehensive introduction to the regulations and requirements ... will be highly interactive, using real life examples ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ... EU Pharmacovigilance Legislation (London, UK - November 16-17, 2015)" ... 15 new EU modules concerning Pharmacovigilance are a major ... in Europe . The intention of ... their requirements, examine how they overlap and fit together ...
(Date:9/2/2015)... Sept. 2, 2015  ArmaGen, Inc., a privately ... to treat severe neurological disorders, announced today that ... multi-center Phase 1/2a clinical trial of AGT-181 in ... AGT-181 is an investigational enzyme ... I. The most severe form of MPS I, ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4
... Sept. 19 Immtech Pharmaceuticals,Inc. (Amex: ... Food and Drug Administration,(FDA) has granted Orphan ... African Trypanosomiasis (HAT), also known as African,sleeping ... numerous,financial and regulatory benefits during pafuramidine,s development,including ...
... Both Cultures and Spores of the ... CHICAGO, Sept. 19 Targanta Therapeutics Corporation,today released ... activity of its,lead antibiotic drug candidate, oritavancin, to ... are being presented today,at the 47th Annual Interscience ...
Cached Medicine Technology:US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 2US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 3Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria 2Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria 3
(Date:9/3/2015)... ... 2015 , ... Global Vision , the world leader in the development ... print and artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. ... London, booth #F33 , Be the first to get a sneak peek of Intelligent ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers ... Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free ... friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... A scar is an unavoidable result of ... near-miraculous example of the body's ability to heal itself. The appearance of a scar is ... the individual's age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their ...
(Date:9/3/2015)... ... 03, 2015 , ... Representatives with State Farm Agent EJ ... Mississippi Gulf Babypalooza on September 19, 2015. , “We will be providing information ... beyond. We will be discussing setting up college funds, offering information specific to ...
(Date:9/3/2015)... Santa Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases ... annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While ... increases to six of every 10 men by age 65, according to the American ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... YORK The Max Cure Foundation and the Samuel Waxman Cancer ... cancer research. With that goal in mind, the two Foundations ... G. Van Meir, Ph.D., of Emory University School of Medicine ... using a small molecule that will target the Ewing sarcoma ...
... July 1 issue of the journal SLEEP shows that ... vigor, fatigue and mood in collegiate basketball players. The ... the athletic performance of actively competing athletes. Results ... time per night during sleep extension was 110.9 minutes ...
... awarded $2.4 million to Allina Hospitals & Clinics to ... pain management for patients at Abbott Northwestern Hospital in ... Health and Healing and the Center for Healthcare Innovation ... study. "Integrative medicine emphasizes a full range of ...
... the Salk Institute for Biological Studies have found clues to ... The protein, p53, can cause cells to stop dividing or ... damage, and it is responsible for much of the tissue ... such as the ones commonly used for cancer therapy. The ...
... the foot just before ground contact during running and walking ... a new study published by a University of Georgia kinesiology ... the June online edition of the American Journal of ... of repetitive ankle sprains demonstrated lower clearance heights between their ...
... June 30 (HealthDay News) -- Women diagnosed with breast cancer ... rates than women who just have breast cancer, according to ... cancer but no chronic illness, those who had conditions such ... or lower survival rate, the study authors reported in the ...
Cached Medicine News:Health News:Targeting the Ewing sarcoma family of tumors 2Health News:Extended sleep improves the athletic performance of collegiate basketball players 2Health News:Extended sleep improves the athletic performance of collegiate basketball players 3Health News:Allina receives NIH grant to study real world usage of integrative therapies 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 3Health News:Foot positioning during walking and running may influence ankle sprains 2Health News:Breast Cancer Plus Other Health Issues Linked to Worse Outcomes 2
Transcranial vascular DWL doppler....
... 9100HS is a powerful automated system capable ... Choose from 6 user-programmable test protocols to ... exam. Any tests not included in the ... be handled using the Doppler, PVR and ...
The CD Horizon M8 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... The VasoGuard from VIASYS Neurocare ... forward in physiologic vascular diagnosis. Exceptional ... and system reliability. , ,VasoGuard delivers ... The unique QuickConnect arm for cuff ...
Medicine Products: